Assignee
Rottapharm Biotech Srl
IT·13 granted patents·5 pending applications·13 citations·filing 2012–2023
Top patents by PatentIndex Score
18 records- 0185US9631029B2Anti-ADAMTS-5 antibody, derivatives and uses thereofRottapharm Biotech Srl·Filed 2013·Granted Apr 25, 2017·9 cites·9 claims
- 0278US9365654B2Anti-TrkA antibodies, derivatives and uses thereofRottapharm Biotech Srl·Filed 2013·Granted Jun 14, 2016·2 cites·5 claims
- 0375US11718582B2(R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonistRottapharm Biotech Srl·Filed 2019·Granted Aug 8, 2023·1 cites·18 claims
- 0474US2024091227A1Use Of 2-Phenyl-6-(1H-Imidazol-1-YL) Quinazoline For Treating Neurodegenerative Diseases, Preferably Alzheimer's DiseaseRottapharm Biotech Srl·Filed 2023·Application pending·0 cites
- 0572US11590114B2Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumoursRottapharm Biotech Srl·Filed 2020·Granted Feb 28, 2023·1 cites·7 claims
- 0669US12544365B2Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumoursRottapharm Biotech Srl·Filed 2022·Granted Feb 10, 2026·0 cites·10 claims
- 0757US2022257598A1Use of 2-Phenyl-6-(1H-Imidazol-1-YL) Quinazoline for Treating Neurodegenerative Diseases, Preferably Alzheimer's DiseaseRottapharm Biotech Srl·Filed 2020·Application pending·0 cites
- 0854US2023000868A1Use of 2-phenyl-6-(1h-imidazol-1-yl) quinazoline for the prevention of abuse and of side effects of at least one opioidRottapharm Biotech Srl·Filed 2020·Application pending·0 cites
- 0951US12433875B2(R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossificationRottapharm Biotech Srl·Filed 2020·Granted Oct 7, 2025·0 cites·14 claims
- 1049US12509446B2FYN and VEGFR2 kinase inhibitorsRottapharm Biotech Srl·Filed 2020·Granted Dec 30, 2025·0 cites·32 claims
- 1147US9498478B2Spiro aminic compounds with NK1 antagonist activityRottapharm Biotech Srl·Filed 2015·Granted Nov 22, 2016·0 cites·6 claims
- 1247US2016244529A1Anti-trka antibodies, derivatives and uses thereofRottapharm Biotech Srl·Filed 2016·Application pending·0 cites
- 1345US12404245B2Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereofRottapharm Biotech Srl·Filed 2021·Granted Sep 2, 2025·0 cites·15 claims
- 1444US9174977B22-azabicyclo[4.1.0]heptane derivatives as orexin receptor antagonists for the treatment of certain disordersRottapharm Biotech Srl·Filed 2013·Granted Nov 3, 2015·0 cites·7 claims
- 1544US2022041559A1Benzo-and pyrido-pyrazoles as protein kinase inhibitorsRottapharm Biotech Srl·Filed 2020·Application pending·0 cites
- 1639US10125121B2FYN kinase inhibitorsRottapharm Biotech Srl·Filed 2015·Granted Nov 13, 2018·0 cites·15 claims
- 1738US9493438B24,4-difluoro-piperidine-compoundsRottapharm Biotech Srl·Filed 2013·Granted Nov 15, 2016·0 cites·24 claims
- 1837US9062033B2Chemical compoundsRottapharm Biotech Srl·Filed 2012·Granted Jun 23, 2015·0 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when Rottapharm Biotech Srl files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →